Last reviewed · How we verify

NCT03448666

ECT-Pembrolizumab in Patients With Unresectable Melanoma With Superficial or Superficial and Visceral Metastases

Withdrawn Phase 2 Last updated 23 September 2024
What this trial tests

Phase 2 trial testing Pembrolizumab in Malignant Melanoma. Withdrawn.

Timeline
1 March 2021
Primary endpoint
1 December 2023
1 December 2023

Quick facts

Lead sponsorEuropean Institute of Oncology
PhasePhase 2
StatusWithdrawn
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposetreatment
Start date1 March 2021
Primary completion1 December 2023
Estimated completion1 December 2023
Sites1 location across Italy

Drugs / interventions tested

Conditions studied

Sponsor

European Institute of Oncology

Who can join

18 and older, any sex, with Malignant Melanoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a Phase 2 multicenter, open label, non-randomized, interventional study enrolling 53 patients.The objectives and purposes of the clinical study described herein are to determine if concomitant Pembrolizumab (Keytruda) and ECT treatments are safe and able to improve local and systemic response rates.ECT will be performed with the CLINIPORATOR and a single IV dose of Bleomycin

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

  1. Electroporation and Immunotherapy-Unleashing the Abscopal Effect.
    Justesen TF, Orhan A, Raskov H, Nolsoe C, et al · · 2022 · cited 38× · PMID 35740542 · DOI 10.3390/cancers14122876
  2. Pulsed Electric Fields in Oncology: A Snapshot of Current Clinical Practices and Research Directions from the 4th World Congress of Electroporation.
    Campana LG, Daud A, Lancellotti F, Arroyo JP, et al · · 2023 · cited 20× · PMID 37444450 · DOI 10.3390/cancers15133340
  3. Electroporation in Head-and-Neck Cancer: An Innovative Approach with Immunotherapy and Nanotechnology Combination.
    Pisani S, Bertino G, Prina-Mello A, Locati LD, et al · · 2022 · cited 17× · PMID 36358782 · DOI 10.3390/cancers14215363
  4. Electrochemotherapy combined with immunotherapy - a promising potential in the treatment of cancer.
    Hadzialjevic B, Omerzel M, Trotovsek B, Cemazar M, et al · · 2023 · cited 15× · PMID 38292489 · DOI 10.3389/fimmu.2023.1336866
  5. Electrochemotherapy and Other Clinical Applications of Electroporation for the Targeted Therapy of Metastatic Melanoma.
    Cucu CI, Giurcăneanu C, Popa LG, Orzan OA, et al · · 2021 · cited 7× · PMID 34300902 · DOI 10.3390/ma14143985
  6. Targeting Genome Stability in Melanoma-A New Approach to an Old Field.
    Osrodek M, Wozniak M. · · 2021 · cited 7× · PMID 33800547 · DOI 10.3390/ijms22073485
  7. Review of Role of Surgery with Electroporation in Melanoma: Chemotherapy, Immunotherapy, and Gene Delivery.
    Ahmad MU, Walsh A, Kirane A. · · 2024 · cited 2× · PMID 38999394 · DOI 10.3390/jcm13133828
  8. Potential dual synergy between electrochemotherapy and sequence of immunotherapies in metastatic melanoma: A case report.
    Morgese F, De Feudis F, Balercia P, Berardi R. · · 2023 · cited 2× · PMID 36761389 · DOI 10.3892/mco.2023.2604

Verify or expand the search:

Other trials of Pembrolizumab

Trials testing the same drug.

Other recruiting trials for Malignant Melanoma

Currently open trials in the same condition.

Other European Institute of Oncology trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03448666.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing